
|Articles|March 22, 2022
Daily Medication Pearl: Asmanex HFA
Author(s)Saro Arakelians, PharmD
Asmanex HFA is a corticosteroid indicated for the maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older
Advertisement
Medication Pearl of the Day: Asmanex HFA 100 mcg (mometasone furoate)
Indication:Asmanex HFA is a corticosteroid indicated for the maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older.
Insight:
- Dosing: In patients 12 years of age and older, 2 inhalations twice daily of Asmanex HFA 100 mcg or 200 mcg.
- Dosage forms: Inhalation aerosol containing 100 mcg or 200 mcg of mometasone furoate per actuation.
- Adverse events: Most common adverse reactions reported in greater than or equal to 3% of patients included nasopharyngitis, headache, sinusitis, bronchitis, and influenza.
- Mechanism of action: Mometasone furoate is a corticosteroid demonstrating potent anti-inflammatory activity.
- Manufacturer: Merck
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
2025 FDA Approvals Highlight the Growing Role of Biomarkers in Breast Cancer
2
IRAKLIA Trial Shows Body Weight Doesn’t Alter Outcomes With On-Body Injector Isatuximab
3
SABCS 2025 Roundup: Advancing Therapy and Precision Care in Breast Cancer
4
Ribociclib Plus Fulvestrant Shows Strong PFS and OS Benefits in Patients With Invasive Lobular Carcinoma
5

















































































































































































































